Evidence map›Paper›PMID 38797942›Full record

ArticleClinical and translational medicine2024

Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF

Peitao Zhang, Lizhao Guan, Wei Sun, Yu Zhang, Yaying Du, Shukai Yuan, Xiaolong Cao, Zhengquan Yu, Qiang Jia, Xiangqian Zheng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Peitao ZhangDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
Lizhao GuanDepartment of Thyroid and Neck Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, China.
Wei SunLaboratory of molecular genetics, School of Medicine, Nankai University, Tianjin, China.
Yu ZhangDepartment of Thyroid and Neck Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, China.
Yaying DuDepartment of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.ORCID 0000-0002-3213-5722
Shukai YuanDepartment of Thyroid and Neck Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, China.
Xiaolong CaoDepartment of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Zhengquan YuState Key Laboratories for Agrobiotechnology, College of Biological Sciences, China Agricultural University, Beijing, China.
Qiang JiaDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
Xiangqian ZhengDepartment of Thyroid and Neck Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhaowei MengDepartment of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, China.
Xingrui LiDepartment of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China.
Li ZhaoDepartment of Thyroid and Neck Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Medical University, Tianjin, China.ORCID 0000-0002-1378-7434

Funding

China Postdoctoral Science Foundation 2022T150475Fundamental Research Funds for the Central Universities 3332022086National Natural Science Foundation of China 81802676National Natural Science Foundation of China 82073052National Natural Science Foundation of China 82273078National Natural Science Foundation of Hubei Province WJ2019M124
6 · The paper itself

Abstract

backgroundBRAF

methodsBioinformatics and clinical specimen analyses, genetic manipulation of BRAF

resultsWe identify miR-31 as a significantly increased onco-miR in BRAF

conclusionsOur findings elucidate a novel BRAF/MAPK-miR-31-Wnt/β-catenin regulatory mechanism underlying clinically BRAF

Indexed as

MicroRNAsProto-Oncogene Proteins B-rafThyroid NeoplasmsAnimalsCarcinogenesisCell DedifferentiationHumansMiceThyroid Cancer, PapillaryBRAF protein, humanBraf protein, mouseMicroRNAsMIRN31 microRNA, humanMirn31 microRNA, mouseProto-Oncogene Proteins B-rafBRAFV600ECEBPADACH1miR‐31papillary thyroid carcinomaWnt/β‐catenin pathway

Identifiers

PMID38797942
PMCPMC11128713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.